[Tocilizumab in COVID-19 patients]

Colaci C, Alfie V, Augustovski F, García Martí S, Bardach A, Ciapponi A, Alcaraz A, Pichon-Riviere A.
Record ID 32018002315
Original Title: Tocilizumab en pacientes con COVID-19
Authors' recomendations: Moderate-quality evidence suggests that using tocilizumab as an add-on to standard therapies, versus not using it, reduces mortality in patients with severe disease and/or in critical condition due to COVID-19, with no higher risk for adverse effects.
Project Status: Completed
Year Published: 2021
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Argentina
MeSH Terms
  • COVID-19
  • SARS-CoV-2
  • Coronavirus Infections
  • Antibodies, Monoclonal, Humanized
Organisation Name: Institute for Clinical Effectiveness and Health Policy
Contact Address: Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name: info@iecs.org.ar
Contact Email: info@iecs.org.ar
Copyright: Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.